Cargando…

Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer

The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative strategy. Nevertheless, the majority of patients surgically resected for pancreatic cancer experiences disease relapse, even when a combination adju...

Descripción completa

Detalles Bibliográficos
Autores principales: Merz, Valeria, Mangiameli, Domenico, Zecchetto, Camilla, Quinzii, Alberto, Pietrobono, Silvia, Messina, Carlo, Casalino, Simona, Gaule, Marina, Pesoni, Camilla, Vitale, Pasquale, Trentin, Chiara, Frisinghelli, Michela, Caffo, Orazio, Melisi, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114435/
https://www.ncbi.nlm.nih.gov/pubmed/35599791
http://dx.doi.org/10.3389/fsurg.2022.866173
_version_ 1784709773855293440
author Merz, Valeria
Mangiameli, Domenico
Zecchetto, Camilla
Quinzii, Alberto
Pietrobono, Silvia
Messina, Carlo
Casalino, Simona
Gaule, Marina
Pesoni, Camilla
Vitale, Pasquale
Trentin, Chiara
Frisinghelli, Michela
Caffo, Orazio
Melisi, Davide
author_facet Merz, Valeria
Mangiameli, Domenico
Zecchetto, Camilla
Quinzii, Alberto
Pietrobono, Silvia
Messina, Carlo
Casalino, Simona
Gaule, Marina
Pesoni, Camilla
Vitale, Pasquale
Trentin, Chiara
Frisinghelli, Michela
Caffo, Orazio
Melisi, Davide
author_sort Merz, Valeria
collection PubMed
description The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative strategy. Nevertheless, the majority of patients surgically resected for pancreatic cancer experiences disease relapse, even when a combination adjuvant therapy is offered. Therefore, aiming at improving disease free survival and overall survival of these patients, there is an increasing interest in evaluating the activity and efficacy of neoadjuvant and perioperative treatments. In this view, it is of utmost importance to find biomarkers able to select patients who may benefit from a preoperative therapy rather than upfront surgical resection. Defined genomic alterations and a dynamic inflammatory microenvironment are the major culprits for disease recurrence and resistance to chemotherapeutic treatments in pancreatic cancer patients. Signal transduction pathways or tumor immune microenvironment could predict early recurrence and response to chemotherapy. In the last decade, distinct molecular subtypes of pancreatic cancer have been described, laying the bases to a tailored therapeutic approach, started firstly in the treatment of advanced disease. Patients with homologous repair deficiency, in particular with mutant germline BRCA genes, represent the first subgroup demonstrating to benefit from specific therapies. A fraction of patients with pancreatic cancer could take advantage of genome sequencing with the aim of identifying possible targetable mutations. These genomic driven strategies could be even more relevant in a potentially curative setting. In this review, we outline putative predictive markers that could help in the next future in tailoring the best therapeutic strategy for pancreatic cancer patients with a potentially curable disease.
format Online
Article
Text
id pubmed-9114435
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91144352022-05-19 Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer Merz, Valeria Mangiameli, Domenico Zecchetto, Camilla Quinzii, Alberto Pietrobono, Silvia Messina, Carlo Casalino, Simona Gaule, Marina Pesoni, Camilla Vitale, Pasquale Trentin, Chiara Frisinghelli, Michela Caffo, Orazio Melisi, Davide Front Surg Surgery The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative strategy. Nevertheless, the majority of patients surgically resected for pancreatic cancer experiences disease relapse, even when a combination adjuvant therapy is offered. Therefore, aiming at improving disease free survival and overall survival of these patients, there is an increasing interest in evaluating the activity and efficacy of neoadjuvant and perioperative treatments. In this view, it is of utmost importance to find biomarkers able to select patients who may benefit from a preoperative therapy rather than upfront surgical resection. Defined genomic alterations and a dynamic inflammatory microenvironment are the major culprits for disease recurrence and resistance to chemotherapeutic treatments in pancreatic cancer patients. Signal transduction pathways or tumor immune microenvironment could predict early recurrence and response to chemotherapy. In the last decade, distinct molecular subtypes of pancreatic cancer have been described, laying the bases to a tailored therapeutic approach, started firstly in the treatment of advanced disease. Patients with homologous repair deficiency, in particular with mutant germline BRCA genes, represent the first subgroup demonstrating to benefit from specific therapies. A fraction of patients with pancreatic cancer could take advantage of genome sequencing with the aim of identifying possible targetable mutations. These genomic driven strategies could be even more relevant in a potentially curative setting. In this review, we outline putative predictive markers that could help in the next future in tailoring the best therapeutic strategy for pancreatic cancer patients with a potentially curable disease. Frontiers Media S.A. 2022-05-04 /pmc/articles/PMC9114435/ /pubmed/35599791 http://dx.doi.org/10.3389/fsurg.2022.866173 Text en Copyright © 2022 Merz, Mangiameli, Zecchetto, Quinzii, Pietrobono, Messina, Casalino, Gaule, Pesoni, Vitale, Trentin, Frisinghelli, Caffo and Melisi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Surgery
Merz, Valeria
Mangiameli, Domenico
Zecchetto, Camilla
Quinzii, Alberto
Pietrobono, Silvia
Messina, Carlo
Casalino, Simona
Gaule, Marina
Pesoni, Camilla
Vitale, Pasquale
Trentin, Chiara
Frisinghelli, Michela
Caffo, Orazio
Melisi, Davide
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
title Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
title_full Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
title_fullStr Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
title_full_unstemmed Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
title_short Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
title_sort predictive biomarkers for a personalized approach in resectable pancreatic cancer
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114435/
https://www.ncbi.nlm.nih.gov/pubmed/35599791
http://dx.doi.org/10.3389/fsurg.2022.866173
work_keys_str_mv AT merzvaleria predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT mangiamelidomenico predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT zecchettocamilla predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT quinziialberto predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT pietrobonosilvia predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT messinacarlo predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT casalinosimona predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT gaulemarina predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT pesonicamilla predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT vitalepasquale predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT trentinchiara predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT frisinghellimichela predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT caffoorazio predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer
AT melisidavide predictivebiomarkersforapersonalizedapproachinresectablepancreaticcancer